- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03381807
Human Amniotic Epithelial Stem Cell in Treatment of Refractory Severe Intrauterine Adhesion
Study Overview
Detailed Description
Asherman's syndrome is an gynecological disorder caused by the destruction of the endometrium due to repeated or aggressive curettages and/or endometritis. As a result, there is a loss of functional endometrium in multiple areas and the uterine cavity is obliterated by intrauterine adhesions, which results in amenorrhea, hypomenorrhea, infertility and recurrent pregnancy loss. Transcervical resection of adhesion (TCRA) is the main treatment for Asherman's syndrome; so far the effect is usually poor in moderate to severe refractory cases.
Human amniotic epithelial stem cells (hAESCs) are derived from human amniotic epithelium. hAESCs retain the characteristics approximating to embryonic stem cells. Animal experiments have shown that the endometrial thickness and fertility of mice was significantly improved after intrauterine therapy with hAESCs. To further explore the role of hAESCs in Asherman's syndrome patients, this project will evaluate the safety of hAESCs and find an effective treatment protocols.
Study Type
Enrollment (Anticipated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Wang Liang
- Phone Number: 0571-88783738
- Email: liangzi1126@126.com
Study Contact Backup
- Name: Liu Yang
- Phone Number: 0571-88783738
- Email: liuyangzheda@163.com
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310009
- Recruiting
- Second Affiliated Hospital, School of Medicine, Zhejiang University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 1. Previously diagnosed as uterine adhesion, after the operation of TCRA and the postoperatively standardized hormonal replacement therapy(HRT) , recently diagnosed with refractory Asherman's syndrome or endometrial atrophy(EA);
- 2. According to the American Fertility Society(AFS) classification in 1988, patients are diagnosed of AS or EA stageⅢ-Ⅳ confirmed by hysteroscopy;
- 3. Elimination of infertility, recurrent spontaneous abortion or hypomenorrhea caused by other diseases;
- 4. Be willing to maintain an HRT cycle medication throughout the study, unless it is not tolerated;
- 5. Normal blood coagulation, liver, heart, and kidney function, absence of HIV, Hepatitis B or C, syphilis and psychiatric pathology;
- 6. Be willing to complete the study and sign the consent form.
Exclusion Criteria:
- 1. Patients with severe internal disease;
- 2. The patients are suffering from gynecologic inflammation or active genital tubercle bacillus;
- 3. The patient has other uterine diseases or the abnormal uterine cavity which can't be restored by surgery;
- 4. Infertility due to a man's cause;
- 5. The patient has a previous history of cancer and is undergoing radiotherapy or chemotherapy;
- 6. HIV positive
- 7. Active hepatitis B or C infection, syphilis seropositive
- 8. Laboratory routine check index abnormality, such as Hb(hemoglobin)<8.0 g/dL,WBC(white blood cell count)<3,000/ml, platelet counts<75 000/mm3, AST(glutamic oxalacetic transaminase)>ULN(upper limit of normal),ALT(Glutamic pyruvic transaminase)>ULN and so on;
- 9. Patients have any complications that may interfere with safety or efficacy or predict life expectancy of less than 24 months;
- 10. Mental illness in the past 6 months;
- 11. Patients have a history of drug or alcohol abuse or dependence in the past two years;
- 12. Unable or unwilling to give informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TCRA and intrauterine infusion of hAESCs
hAESCs is infused into uterine cavity after TCRA.
|
5*10^7 hAESCs is infused into uterine cavity with TCRA on Day0, Day7 and after the first menstruation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
changes of Endometrial thickness
Time Frame: at the 1, 3,6 and 9 months after surgery
|
Measure the endometrial thickness during periovulatory period on ultrasound by the same trained medical sonographers at 1,3,6 and 9 months after surgery, comparing with pre-operation.
|
at the 1, 3,6 and 9 months after surgery
|
changes of Menstrual blood volume
Time Frame: at the 1, 3,6 and 9 months after surgery
|
Estimate the menstrual blood volume after surgery by the number of sanitary napkins per day and number of days to menstruation at 1, 3, 6, 9 months after surgery, which will be compared with pre-operation.
|
at the 1, 3,6 and 9 months after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
pregnancy rate
Time Frame: 24 months
|
Ultrasound reveals that the fetus had a heart activity
|
24 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Wang Liang, The Second Affiliated Hospital of Medical College of Zhejiang University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017-080
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intrauterine Adhesion
-
Hua DuanRecruitingIntrauterine Adhesion | Database for Intrauterine Adhesion | Risk Factors for Intrauterine Adhesion | Risk Stratification and Prognostic AssessmentChina
-
The Fourth Affiliated Hospital of Zhejiang University...Recruiting
-
Rejoni Inc.CompletedIntrauterine AdhesionUnited States
-
Ain Shams Maternity HospitalCompletedIntrauterine AdhesionEgypt
-
Fu Xing Hospital, Capital Medical UniversityBeijing Tiantan HospitalUnknown
-
Rejoni Inc.RecruitingIntrauterine AdhesionUnited States
-
Limin FengRecruitingIntrauterine AdhesionChina
-
Fu Xing Hospital, Capital Medical UniversityRecruitingIntrauterine AdhesionChina
-
WomedCompletedIntrauterine AdhesionBelgium, France, Netherlands
-
Qi ZhouTongji HospitalUnknown
Clinical Trials on hAESCs
-
Shanghai East HospitalShanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaRecruitingIdiopathic Parkinson's DiseaseChina
-
Shanghai East HospitalShanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaNot yet recruitingParkinson's DiseaseChina